News Agency
The Times Real Estate

Reistone Biopharma's oral Ivarmacitinib Meets Primary Endpoint in Phase III Study for Atopic Dermatitis

  • Written by PR Newswire
Reistone Biopharma's oral Ivarmacitinib Meets Primary Endpoint in Phase III Study for Atopic Dermatitis

SHANGHAI, Nov. 15, 2022 /PRNewswire/ -- Reistone Biopharma (Reistone), a leading biotech company focused on development of innovative medicines for immune and inflammation diseases, today announced positive results from a Phase III study – QUARTZ3 (NCT04875169)evaluating the efficacy and safety of once daily Ivarmacitinib as monotherapy in...

Read more: Reistone Biopharma's oral Ivarmacitinib Meets Primary Endpoint in Phase III Study for Atopic...

How Website Speed Matters for Ecommerce Business?

In the competitive landscape of eCommerce, where every second counts, website speed is a critical factor that can make or break your business. For eCommerce businesses in Melbourne, the importance of a fast-loading website extends beyond mere aesthetics; it directly... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion